Brief: Sonnet Biotherapeutics Announces Interim Data In Two Phase 1 Dose-Escalation Trials Of Son-1010

Sonnet Biotherapeutics Holdings

02/11/2022 15:25

Nov 2 (Reuters) - Sonnet Biotherapeutics Holdings Inc
 SONN.O :
    * SONNET BIOTHERAPEUTICS ANNOUNCES INTERIM DATA IN TWO PHASE
1
DOSE-ESCALATION TRIALS OF SON-1010
    * SONNET BIOTHERAPEUTICS ANNOUNCES INTERIM DATA IN TWO PHASE
1
DOSE-ESCALATION TRIALS OF SON-1010
    * SONNET BIOTHERAPEUTICS HOLDINGS INC -  SB101 AND SB102
STUDIES
HAVE TOGETHER DOSED 36 SUBJECTS TO DATE AS DOSE ESCALATION
CONTINUES
    * SONNET BIOTHERAPEUTICS -  ADVERSE EVENTS HAVE BEEN
MILD/MODERATE, TRANSIENT IN NATURE, AND HAVE ALL BEEN TOLERABLE
IN SB101 AND SB102

Source text for Eikon: [https://bit.ly/3sTBmVI]
Further company coverage:  SONN.O 
 ((Reuters.Briefs@thomsonreuters.com;;))